UBS analyst Trung Huynh says Novo Nordisk’s (NVO) CagriSema Phase 3 topline obesity data “underwhelmed,” a positive read-through to Eli Lilly (LLY) and Amgen (AMGN). CagriSema achieved an average weight loss of 20.4%, below Novo’s prior guidance of 25% and inferior to Lilly’s tirzepatide at a similar timepoint, the analyst tells investors in a research note. UBS views the CagriSema’s obesity readout a positive read-through to Lilly, “validating again tirzepatide’s best-in-class profile.” It also views Novo’s updates a positive read-through to Amgen, saying CagriSema’s efficacy now seems mostly in-line with MariTide, with likely gastrointestinal intolerability issues, and could appear less attractive with MariTide being a monthly titration regimen.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LLY:
- Weight loss seen with Novo’s CagriSema weaker than expected, says BofA
- Eli Lilly’s (NYSE:LLY) Zepbound Shortage Over, Says FDA
- End to tirzepatide shortage has read on Hims GLP-1 trajectory, says Leerink
- Hims & Hers falls after FDA ends shortage of Lilly weight loss drug
- Trump’s Key Advisors Are Split on Whether Medicare Should Cover Weight-Loss Drugs
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
